APGE vs. QGEN, RGEN, PCVX, EXEL, RVMD, HALO, CRSP, KRYS, IBRX, and IMVT
Should you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Exelixis (EXEL), Revolution Medicines (RVMD), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), ImmunityBio (IBRX), and Immunovant (IMVT). These companies are all part of the "biological products, except diagnostic" industry.
Apogee Therapeutics (NASDAQ:APGE) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.
Apogee Therapeutics presently has a consensus price target of $73.00, indicating a potential upside of 76.12%. Qiagen has a consensus price target of $50.95, indicating a potential upside of 14.08%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Apogee Therapeutics is more favorable than Qiagen.
79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 36.1% of Apogee Therapeutics shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Qiagen had 9 more articles in the media than Apogee Therapeutics. MarketBeat recorded 10 mentions for Qiagen and 1 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.79 beat Qiagen's score of 0.61 indicating that Apogee Therapeutics is being referred to more favorably in the media.
Qiagen has a net margin of 17.38% compared to Apogee Therapeutics' net margin of 0.00%. Qiagen's return on equity of 12.59% beat Apogee Therapeutics' return on equity.
Qiagen received 229 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
Qiagen has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Summary
Qiagen beats Apogee Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Apogee Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apogee Therapeutics Competitors List
Related Companies and Tools
